Could a new drug combo wipe out three parasitic diseases at once?

NCT ID NCT07159373

Not yet recruiting Disease control Sponsor: Medicines Development for Global Health Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This large study in Fiji tests whether a new combination of drugs (moxidectin plus two others) can safely treat three common parasitic infections: lymphatic filariasis, scabies, and strongyloidiasis. About 5,100 people will receive either the new combo or the standard treatment once a year for three years. The goal is to see if the new combo clears the infections better and with similar side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: moxidectin (combined with diethylcarbamazine and albendazole)
What this could lead to: If successful, this could provide a safer or more effective way to control and eventually eliminate these parasitic diseases in affected communities.
What could go wrong: This is a large Phase 3 trial, but results may not apply to all regions. Side effects are possible, and the treatment may not work better than the existing option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LYMPHATIC FILARIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

filarial elephantiasis filariasis scabies strongyloidiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHATIC FILARIASIS SCABIES STRONGYLOIDIASIS

Contacts and locations

Locations

Ministry of Health and Medical Services Fiji

Suva, Fiji

More trials for these conditions

Other studies related to the condition(s) this trial covers.